Is MTHFR A1298C less strongly linked to elevated homocysteine and cardiovascular risk than C677T?

The MTHFR gene plays a crucial role in folate metabolism, but its two primary variants, C677T and A1298C, differ significantly in their clinical and metabolic consequences.

Clinical and cardiovascular risk evidence

• MTHFR C677T: Homozygous (TT) individuals face a modest but consistent increase in coronary heart disease risk, with odds ratios (OR) typically ranging from 1.1 to 1.2.
• MTHFR A1298C: This variant exhibits much weaker and often non-significant independent associations with coronary artery disease and myocardial infarction, with highly heterogeneous models showing only marginal associations (OR 1.18–1.27).

Mechanistic pathways and enzyme activity

• Enzyme compromise: The thermolabile C677T variant reduces MTHFR enzyme activity to approximately 30% in TT homozygotes. This reduction leads to 20% to 25% higher fasting plasma homocysteine levels, particularly in low-folate environments.
• Milder impact: The A1298C variant is less disruptive, preserving about 60% of enzyme activity in CC homozygotes. Consequently, it does not cause clinically significant fasting homocysteine elevations in isolation, though compound heterozygosity (inheriting one of each variant) does restrict overall enzyme function.

Downstream functional testing

• Phenotypic readout: Measuring total plasma homocysteine serves as a direct biochemical readout of downstream metabolic impairment, successfully integrating genetic predisposition with environmental factors like folate and vitamin B12 status.
• Clinical utility: Because genetic variants alone do not dictate clinical pathology, major organizations like ACMG and ACOG discourage routine MTHFR genotyping. Direct plasma homocysteine testing offers superior clinical utility by assessing actual enzymatic function.

Bottom line

The MTHFR A1298C variant has a substantially weaker impact on enzyme function and cardiovascular risk than the C677T variant. Because genetic presence does not guarantee metabolic dysfunction, measuring plasma homocysteine is the most effective clinical method to determine the actual downstream phenotypic impact.